Durata Therapeutics to Present at JMP Securities Healthcare Conference
July 02, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, July 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the 8th Annual JMP Securities Healthcare...
Durata Therapeutics to Present at Jefferies 2013 Global Healthcare Conference
May 29, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Jefferies 2013 Global Healthcare...
Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors
May 16, 2013 13:44 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 16, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Paul A. Friedman, M.D. was elected to its Board of Directors at the Company's 2013 Annual Meeting of...
Durata Therapeutics, Inc. Reports First Quarter 2013 Financial Results
May 09, 2013 07:00 ET
|
Durata Therapeutics, Inc.
-Raised $54 million in Recent Equity Offering-
CHICAGO, May 9, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended March 31,...
Durata Therapeutics to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
May 07, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Bank of America Merrill Lynch...
Durata Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013
May 02, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 9 at 8:30 a.m. Eastern Time to discuss first quarter 2013...
New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID Meeting
April 29, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from surveillance results of its lead product candidate, dalbavancin, under investigation for...
Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting
April 29, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from a Phase 1 study of its lead product candidate, dalbavancin, under investigation for the...
Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting
April 24, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be...
Durata Therapeutics to Present at the 2013 Needham Healthcare Conference
April 22, 2013 15:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 22, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will be presenting at the Needham 12th Annual Healthcare Conference. The formal...